Insulin Legislation Gains Momentum with Bipartisan Support

Bipartisan efforts to cap insulin costs at $35 per month for individuals with private insurance are gaining traction. The bill, which was introduced in March, has recently gained four additional co-sponsors: Senators Joni Ernst (R-Iowa), John Hickenlooper (D-Colo.), Kevin Cramer (R-N.D.), and Angela Alsobrooks (D-Md.).

The proposed legislation now boasts 22 bipartisan co-sponsors, reflecting Congress’s initiative to address healthcare affordability. A KFF survey from April indicated that healthcare costs remain a major concern for many.

The legislation, previously introduced in 2023 with 13 co-sponsors including seven Republicans, stalled in the committee stage. The current bill is a collaborative effort by Democratic Senators Jeanne Shaheen (N.H.), Raphael Warnock (Ga.), and Republicans Susan Collins (Maine) and John Kennedy (La.). Its goal is to extend the existing $35 cap for Medicare patients — established by the Inflation Reduction Act — to other plans including those available on the ObamaCare marketplaces and commercial plans.

Additionally, the bill proposes a pilot program offering uninsured diabetes patients insulin at $35 per month in 10 states. It aims to require group and individual market health plans to waive deductibles and limit cost-sharing to either $35 or 25% of the list price monthly for at least one insulin type and dosage form.

Legislators are likely to integrate this legislation into essential end-of-year bills, including healthcare program extensions.

Other Developments in Healthcare Policy:

• The Department of Health and Human Services (HHS) announced enhancements to nutrition requirements in U.S. medical education, with eight medical organizations agreeing to improve nutrition standards across educational levels.
• The hemp industry’s supporters are pressing Congress to prevent a looming ban on hemp-derived intoxicants, which could come into effect in November.
• Former President Trump announced an addition of 160 prescription medications to TrumpRx, his administration’s drug platform, bringing the total to over 800 discounted drugs.